Printer Friendly

Pathologic Findings of Breast Lesions Detected on Magnetic Resonance Imaging.

During the last 20 years, magnetic resonance imaging (MRI) has emerged as the most sensitive imaging technique for detecting breast cancers. Currently it is used for evaluation of extent of disease in patients with newly diagnosed breast cancer, screening of high-risk patients for early diagnosis of cancer, additional evaluation of indeterminate breast abnormalities identified by mammography or sonography, and evaluation of response to neoadjuvant systemic therapy. (1-4) In breast MRI, a lesion's level of suspicion is based on whether or not it displays contrast enhancement, the speed and pattern of enhancement (ie, kinetics), and the morphologic characteristics of the lesion. Magnetic resonance imaging-guided biopsy is performed when a suspicious finding cannot be adequately detected by mammographic or ultrasound evaluation. The increase in the number of MRI-guided breast biopsies within the last 5 years parallels the increase in the total number of breast MRI studies performed for all indications. Since a large number of these lesions are benign, it has become apparent that the high sensitivity of this imaging modality is challenged by its low specificity. This, in turn, has sparked controversies regarding the increasing use of breast MRI with increased rates of unnecessary mastectomy, increased workups, delay to definitive surgery, and limited evidence of improved clinical outcomes even with the added costs. (1,5-7)

Radiology-pathology correlation has helped to improve patient care. (8,9) Previous radiologic-pathologic correlation studies have involved mostly ultrasound-guided core needle and some stereotactic-guided core biopsies. (10-14) Of the correlation studies pertaining to MRI, most are found within the radiology literature, but a few studies appear in pathology sources. (15-20) It is important for pathologists to understand this imaging technique and be familiar with the entities that can present as an abnormal enhancing lesion on MRI. The purpose of this study is to identify the spectrum of pathologic changes that present as abnormal enhancing lesions and to determine if any specific MRI pattern correlates with malignant lesions.

MATERIALS AND METHODS

Study Population

The institutional review board approved the study and granted a waiver of informed consent. The pathology and radiology databases at University of Texas Southwestern Medical Center (Dallas) were searched to identify all MRI-guided breast biopsies. Cases from October 2007 through September 2012 were included in the study. Radiology and pathology reports were correlated for each case to ensure each core biopsy was obtained with MRI guidance for inclusion in the study. Of the 2861 MRI scans performed during this period, we identified 177 MRI-guided breast core biopsies performed on 152 patients for inclusion. Magnetic resonance imaging indications, MRI features (including lesion type and kinetic patterns), pathologic findings, and patient demographics were subsequently reviewed and recorded.

MRI Data Acquisition and Review

Dynamic contrast-enhanced MRI was performed with an Intera 1.5T system (Philips Medical Systems, Andover, Massachusetts) and a 7-channel bilateral breast coil (XR MammoTrak, Invivo, Gainesville, Florida). For the vast majority of MRI examinations, the following MRI sequences were obtained: axial 3-dimensional nonfat suppressed T2-weighted and axial 3-dimensional fat-suppressed Tl-weighted precontrast, followed by 4 dynamic postcontrast axial 3-dimensional fat-suppressed T1-weighted precontrast images at approximately 1-minute intervals.

All available prebiopsy MRI images were reviewed by a fellowship-trained breast-imaging radiologist without knowledge of the pathologic findings. All studies were evaluated retrospectively with a commercial computer-aided detection system (DynaCAD version 2.1, Invivo). Each lesion was categorized as mass, nonmass, or focus enhancement, and further characterized by the Breast Imaging Reporting and Data System (BI-RADS) lexicon. (35) Time-signal intensity curve patterns obtained from the dynamic contrast-enhanced MRI data were categorized as slow, medium, and rapid for the initial wash-in phase and persistent, plateau, and washout for the delayed-kinetics phase. All MRI biopsies were performed using an MRI-compatible 9-gauge directional vacuum-assisted biopsy device (ATEC, Suros Surgical Systems, Hologic, Inc, Marlborough, Massachusetts).

Assessment of the MRI-Guided Biopsy

For the study, all the biopsies were reviewed to confirm the original interpretation and to determine any dominant pathologic finding that would have correlated with the radiologic findings of mass, nonmass, or focus enhancements. Each core biopsy was examined by hematoxylin-eosin-stained slides cut at 3 different levels per paraffin block. The slides were reviewed by 3 breast pathologists. The malignant lesions were categorized as invasive carcinomas or ductal carcinoma in situ (DCIS). Biopsies that showed atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or flat epithelial atypia were grouped as atypical epithelial lesions. The lesions in the benign category were subcategorized into benign breast diagnoses and unremarkable/normal breast tissue. The benign breast diagnoses included proliferative and nonproliferative breast diseases, miscellaneous benign findings such as intramammary lymph node, fat necrosis, and hemangioma. The breast tissue that did not reveal any specific pathologic abnormality other than normal glandular elements with or without dense stroma was categorized as normal breast tissue for the study. Lesions were classified as fibrocystic change with or without epithelial hyperplasia if the lesion had apocrine metaplasia, nodular adenosis, sclerosing adenosis, papillomatosis, and usual ductal hyperplasia. Lesions labeled as columnar cell lesions included columnar cell change and/or columnar cell hyperplasia. Some of the columnar cell lesions had associated pseudoangiomatous stromal hyperplasia or concomitant fibrocystic change. The miscellaneous lesions were specific findings and were recorded as such.

RESULTS

Table 1 summarizes the patient population, indications for MRI evaluation, and the number of patients in each category. We identified 177 MRI-guided biopsies in 152 patients. Patient age ranged from 27 to 83 years, with a mean of 52 years. The most common indication for MRI was to determine the extent of disease (43%; 66 of 152), followed by screening of high-risk women (39%; 59 of 152), which included those with a strong family history or carriers of BRCA1 or BRCA2 mutations or other rare gene mutations that increased breast cancer risk. The remaining biopsies (18%; 27 of 152) were performed to follow up an incomplete evaluation or indeterminate lesion. The median and mean sizes of MRI lesions were 10 and 14 mm, respectively (range, 5-80 mm). The mass lesions ranged from 5 to 40 mm (median, 8 mm), and the nonmass lesions ranged from 5 to 80 mm (median, 15 mm). All focus lesions measured 5 mm or less.

The vast majority (82%; 145 of 177) of biopsied lesions were BI-RADS 4, followed by BI-RADS 3 (8%; 13 of 177); BI-RADS 5 and 6 constituted 8% of cases. Only 2% (4 of 177) of the lesions did not have a completed evaluation for BI-RADS assessment. The lesions targeted via MRI were mostly mass lesions (54%; 95 of 177), followed by nonmass lesions (44%; 76 of 177). The largest number of biopsied lesions (42%; 74 of 177) showed persistent kinetics, followed by plateau (25%; 44 of 177) and washout kinetics (17%; 30 of 177). Due to imaging protocol limitations, kinetic assessment was not available for 16% (29 of 177) of lesions, most of which were performed in 2007 and early 2008 (Table 1).

Table 2 summarizes the different categories of pathologic diagnosis in different patient populations based on the MRI indication. Of all the malignant cases in our study, the majority (61%; 19 of 31) were identified in the group undergoing MRI evaluation for extent of disease, followed by those undergoing high-risk screening (23%; 7 of 31). Malignancy was identified in 14% (5 of 35) of indeterminate lesions.

Overall, 18% (31 of 177) of biopsies were malignant, of which 61% (19 of 31) were invasive carcinoma and 39% (12 of 31) were DCIS (Table 3). The remaining 82% (146 of 177) of MRI-guided biopsies were nonmalignant, of which 71% (126 of 177) revealed benign changes (or no pathologic findings) and 11% (20 of 177) showed epithelial atypia, which includes 17 cases of lobular neoplasia and 3 cases of atypical ductal hyperplasia. Some of the atypical epithelial changes were identified in a background of benign changes. All 3 atypical ductal hyperplasia were focal. One did not reveal additional atypia on excision, one was lost to follow-up, and the last one revealed DCIS on excision.

Figure 1 demonstrates the percentages of benign, atypical, and malignant diagnosis in the different categories of MRI lesions. Sixty-five percent (62 of 95) of the mass lesions and 76% (58 of 76) of nonmass enhancing lesions were benign. All 6 MRI focus lesions were benign. Only 21% (20 of 95) of the mass lesions and 14% (11 of 76) of nonmass lesions were malignant.

Dynamic contrast-enhanced MRI kinetics were compared in the benign, atypical, and malignant categories (Figure 2). Of the MRI lesions with persistent kinetics, the vast majority (84%; 62 of 74) were benign (Figure 3, A through C). Lesions with plateau kinetics portend an indeterminate level of suspicion. The majority (70%; 31 of 44) of lesions with this kinetic pattern were benign (Figure 4, A through C). Out of 30 lesions with washout kinetics, 57% (17 of 30) were benign and 30% (9 of 30) were malignant (Figure 5, A through C).

Figure 6 describes the distribution of different kinetic patterns in all malignant lesions. Most of the malignant mass lesions (40%; 8 of 20) showed washout kinetics (Figure 7, A through C), whereas the majority of nonmass lesions exhibited persistent or plateau kinetics (Figures 6 and 8, A through C). Fifteen of the 19 invasive carcinomas were mass lesions, and the remaining 4 showed nonmass enhancements (3 invasive lobular carcinomas, 1 invasive ductal carcinoma). The invasive lesions did not show a specific kinetic pattern (5 with washout kinetics, 4 showing persistent kinetics, and 4 with plateau kinetics). The size of the lesions ranged from 5 to 70 mm (median, 9 mm). Seven DCIS cases presented as nonmass enhancements and 5 as mass enhancements. Most DCIS cases (9 of 12) showed plateau or washout kinetics. These lesions ranged in size from 7 to 46 mm (median, 12.5 mm). The majority of the DCIS cases were high-grade type (8 of 12).

Magnetic resonance imaging features and kinetics were also examined in all benign lesions (Figure 9). These lesions were most commonly masses (49%; 62 of 126), closely followed by nonmass lesions (46%; 58 of 126). Although nearly half (62 of 126; 49%) of these lesions had persistent kinetics, 13% (17 of 126) of benign lesions showed washout kinetics.

Table 3 lists different benign lesions and "unremarkable/Normal" breast tissue (71% of all MRI-guided biopsies; 126 of 177). Fibrocystic changes comprised the largest number of the benign breast cases, closely followed by columnar cell lesions. The remaining lesions included fibroadenomas, hemangioma, duct ectasia, pseudoangiomatous stromal hyperplasia, fat necrosis, and intramammary lymph nodes.

Follow-up of the 20 patients (21 biopsies) who had unremarkable/normal breast tissue on MRI-guided biopsy revealed the following: 11 patients had resolution of the initial lesion on follow-up MRI, 1 patient had a prophylactic mastectomy with concordant benign pathology at the 2 MRI biopsy sites, 4 women underwent rebiopsy that yielded benign breast tissue or fibrocystic changes, 3 women were lost to follow-up, and 1 had a follow-up ultrasound guided biopsy that revealed focal lobular carcinoma in situ in a background of columnar cell change.

DISCUSSION

Dynamic contrast-enhanced MRI has emerged as a highly sensitive (88%-92%) technique for evaluation of breast lesions, but the specificity associated with this method ranges from 67% to 77%. (4,21) In breast MRI, lesions are characterized based on their morphologic features and dynamic contrast enhancement and kinetic pattern such as signal intensity or speed of enhancement combined with morphologic patterns. (21) The initial upslope (early phase enhancement) equates to signal intensity during the first 2 minutes following contrast administration. It is described as slow, medium, or rapid depending on the steepness of the curve (enhancement velocity). The delayed phase begins after peak enhancement, usually within 2 minutes, and is characterized as persistent if it continues to rise, plateau if it levels off, and washout if it drops off (Figure 10). Persistent kinetics is generally aligned more with benign lesions, washout kinetics is generally regarded as suspicious for malignancy, and plateau kinetics are considered indeterminate.

Morphologically, lesions are separated into enhancing masses, nonmass enhancements, and foci. Masses are 3-dimensional space-occupying lesions, which are further characterized by shape, margin, and internal enhancement characteristics. Nonmass enhancements have an absence of distinct 3-dimensional or masslike features, and are characterized by distribution, internal patterns, and symmetry or asymmetry between breasts. A focus lesion measures less than 5 mm and cannot be further characterized by shape or margin status. (22,23) Example descriptions of suspicious MRI lesions would include "irregular spiculated mass with rim enhancement" or "linear clumped nonmass enhancement."

The BI-RADS lexicon, now in its fifth edition, standardizes the reporting of MRI-detected lesions. The lexicon standardizes the approach to assigning morphology and enhancement characteristics for lesions and has overall improved the diagnostic specificity of the lesions detected by MRI. (22,23) Although combining these features has improved the overall diagnostic specificity of MRI, in our study only 18% (31 of 177) of the biopsied lesions revealed malignancy.

Lesions that show washout kinetics favor a malignant process, whereas those that show persistent kinetics favor a benign process. As expected, the majority of benign lesions in our study showed persistent (49%; 62 of 126) or plateau (25%; 31 of 126) kinetics, but interestingly, 13% (17 of 126) of the benign lesions exhibited more suspicious washout kinetics. Of the benign lesions, 49% (62 of 126) were described as mass lesions, of which 21% (13 of 62) had washout kinetics. Only one focus lesion showed washout kinetics. Among the benign lesions that showed a washout kinetic pattern, fibrocystic changes comprised 35% (6 of 17), closely followed by normal breast tissue (24%; 4 of 17) and columnar cell lesions (12%; 2 of 17). The remaining lesions with this kinetic pattern were radial scars, intraductal papilloma, fibroadenoma, and duct ectasia. Most malignant lesions showed either washout or plateau kinetics (29% in each category; 9 of 31), as expected, but 16% (5 of 31) of malignant lesions demonstrated persistent kinetics (2 invasive duct carcinomas, 2 invasive lobular carcinomas, and 1 DCIS). These results highlight the overlap in MRI features between benign and malignant lesions. It is important to note that malignant lesions such as invasive lobular carcinoma and some DCIS may not present as mass lesions or show washout kinetics. This is further compounded by the fact that many lesions that present as a mass with washout kinetics (21% in our study; 13 of 62) can be benign, making it difficult to determine how suspicious a lesion is for malignancy.

A variety of benign breast conditions have been previously described to mimic malignancy on MRI. Some of these entities include radial scar, sclerosing adenosis, fibroadenoma, fat necrosis, and pseudoangiomatous stromal hyperplasia. (24) In our study, more than half of the benign lesions were fibrocystic change with or without epithelial hyperplasia, followed by columnar cell lesions. Interestingly, one-fourth of all the benign biopsies had columnar cell lesions, alone or associated with pseudoangiomatous stromal hyperplasia or other proliferative changes such as usual ductal hyperplasia. Apocrine metaplasia was described as a frequent biopsy finding in MRI-guided biopsies in one study (38%; 11 of 29 cases). (15) However, in our study, 10 cases showed cystic apocrine metaplasia, mostly as one of the findings in the fibrocystic change category, with the exception of 1 case where apocrine metaplasia was the only finding. A recent study showed that increased microvascular density in select benign breast lesions, notably cystic apocrine metaplasia when compared with normal fibroglandular tissue, led to their detection on MRI as an enhancing focus or small mass. (25) In our study, a large spectrum of benign changes showed abnormal enhancement. Most of the benign lesions had some form of proliferative change, inflammatory reaction, or reactive changes; the associated increased vascularity and the localized nature of the abnormality led to their detection on MRI.

Atypical hyperplasia, both ductal and lobular type, may be the most significant lesion found on MRI-guided biopsy, but may not necessarily be the lesion being targeted by imaging, as it is usually incidental or quantitatively too small. However, in certain instances these lesions represent a dominant finding, as in lobular carcinoma in situ. (26,27)

Normal breast tissue can show significant enhancement depending on the phase of the menstrual cycle, further complicating image interpretation. (1,24) Twenty-one of our biopsies showed normal breast tissue, of which 11 patients had follow-up imaging studies documenting resolution of the initial lesion, 4 patients had repeat biopsies showing either benign breast tissue or fibrocystic changes, and 1 patient underwent total mastectomy with concordant results. This finding confirms that morphologically normal-appearing breast tissue can show segmental or focal enhancement. However, on rare occasions, there may be sampling error, which occurred in one case in our study where a subsequent ultrasound guided biopsy of the area revealed focal lobular carcinoma in situ in a background of columnar cell lesion. Excluding 3 cases that were lost to follow-up, there were no cases in our series that revealed a missed malignancy on follow-up examination or repeat biopsy. In summary, finding normal-appearing breast tissue on an MRI-guided biopsy should not automatically raise the possibility of sampling error, but should be correlated with other findings and follow-up. However, any growth of a sampled lesion showing normal tissue should prompt rebiopsy and further histologic confirmation.

The rate of detecting malignancy on MRI is variable and depends on the study design and the patient population being evaluated. Prior studies have shown overall malignancy rates of 22% to 29%. (28,29) The overall rate of malignancy identified in our study was slightly lower (18%; 31 of 177). The highest percentage of malignancy was identified in patients who were being evaluated for extent of disease in our study (25%; 19 of 77), a finding similar to those of other studies. (2,28,29) Magnetic resonance imaging screening in high-risk women who have a strong family history, known genetic predisposition, or history of prior radiation can detect malignancy in 10% to 33% of cases. (28-30) In our study, 11% (7 of 65) of biopsies were classified as malignant in this particular population (4 invasive carcinomas, including 1 tubular carcinoma and 3 DCIS). Lastly, follow-up of 35 indeterminate lesions found malignancy in 14% (5 of 35) of cases.

In summary, the likelihood of discovering an undetected malignancy on MRI is higher in those with a new cancer diagnosis compared with those undergoing screening or further workup for indeterminate lesions. The specificity of MRI is significantly lower than that of screening mammography. However, when MRI or ultrasound is used in conjunction with traditional mammography, it yields a higher rate of cancer detection. (31-34) Nevertheless, the increased sensitivity of MRI leads to detection of a large number of benign lesions, thus increasing the number of biopsy procedures and added cost. This may change in the future if significant improvement occurs in MRI techniques to increase specificity, thereby reducing the number of false-positive MRI findings. (3)

In conclusion, MRI detects a wide spectrum of benign findings as suspicious lesions. Many benign lesions show morphologic and kinetic features similar to malignant lesions on MRI. Because MRI is highly sensitive but not specific, pathologists will continue to play an important role in the final diagnosis of these lesions. It is important that we understand the strengths and weaknesses of this imaging modality and ensure adequate communication regarding radiologic-pathologic correlation of these biopsies for optimal patient care.

References

(1.) Landercasper J, Linebarger JH. Contemporary breast imaging and concordance assessment: a surgical perspective. Surg Clin North Am. 2011; 91(1):33-58.

(2.) Teller P, Jefford VJ, Gabram SG, Newell M, Carlson GW. The utility of breast MRI in the management of breast cancer. Breast J. 2010;16(4):394-403.

(3.) Heywang-Kobrunner SH, Hacker A, Sedlacek S. Magnetic resonance imaging: the evolution of breast imaging. Breast. 2013;22(suppl 2):S77-S82.

(4.) Peters NH, Borel Rinkes IH, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology. 2008;246(1):116-124.

(5.) Morrow M, Harris JR. More mastectomies: is this what patients really want? J Clin Oncol. 2009;27(25):4038-4040.

(6.) Solin LJ. Counterview: pre-operative breast MRI (magnetic resonance imaging) is not recommended for all patients with newly diagnosed breast cancer. Breast. 2010;19(1):7-9.

(7.) Kuhl CK. The changing world of breast cancer: a radiologist's perspective. Plast Surg Nurs. 2016;36(1):31-49.

(8.) Prakash S, Venkataraman S, Slanetz PJ, et al. Improving patient care by incorporation of multidisciplinary breast radiology-pathology correlation conference. Can Assoc Radiol J. 2016;67(2):122-129.

(9.) Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am. 2000;38(4):791-807.

(10.) Crystal P, Koretz M, Shcharynsky S, Makarov V, Strano S. Accuracy of sonographically guided 14-gauge core-needle biopsy: results of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions. J Clin Ultrasound. 2005;33(2):47-52.

(11.) Schueller G, Jaromi S, Ponhold L, et al. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology. 2008;248(2): 406-413.

(12.) Tse GM, Tan PH, Cheung HS, Chu WC, Lam WW. Intermediate to highly suspicious calcification in breast lesions: a radio-pathologic correlation. Breast Cancer Res Treat. 2008;110(1):1-7.

(13.) Neal L, Sandhu NP, Hieken TJ, et al. Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Mayo Clin Proc. 2014;89(4):536-547.

(14.) Zuiani C, Londero V, Bestagno A, et al. Proliferative high-risk lesions of the breast: contribution and limits of US-guided core biopsy. Radiol Med (Torino). 2005;110(5-6):589-602.

(15.) Siziopikou KP, Jokich P, Cobleigh M. Pathologic findings in MRI-guided needle core biopsies of the breast in patients with newly diagnosed breast cancer. Int J Breast Cancer. 2011;2011:613285.

(16.) Cornea V, Jaffer S, Bleiweiss IJ, Nagi C. Adequate histologic sampling of breast magnetic resonance imaging-guided core needle biopsy. Arch PatholLab Med. 2009;133(12):1961-1964.

(17.) Dratwa C, Jalaguier-Coudray A, Thomassin-Piana J, et al. Breast MR biopsy: pathological and radiological correlation. Eur Radiol. 2016;26(8):2510-2519.

(18.) Heller SL, Hernandez O, Moy L. Radiologic-pathologic correlation at breast MR imaging: what is the appropriate management for high-risk lesions? Magn Reson Imaging Clin N Am. 2013;21(3):583-599.

(19.) Orel SG, Rosen M, Mies C, Schnall MD. MR imaging-guided 9-gauge vacuum-assisted core-needle breast biopsy: initial experience. Radiology. 2006; 238(1):54-61.

(20.) Choudhery S, Lynch B, Sahoo S, Seiler SJ. Features of non-mass enhancing lesions detected on 1.5 T breast MRI: a radiologic and pathologic analysis. Breast Dis. 2015;35(1):13-17.

(21.) Medeiros LR, Duarte CS, Rosa DD, et al. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis. Breast Cancer Res Treat. 2011;126(2):273-285.

(22.) Agrawal G, Su MY, Nalcioglu O, Feig SA, Chen JH. Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon. Cancer. 2009;115(7):1363-1380.

(23.) Erguvan-Dogan B, Whitman GJ, Kushwaha AC, Phelps MJ, Dempsey PJ. BIRADS-MRI: a primer. AJR Am J Roentgenol. 2006;187(2):W152-W160.

(24.) Iglesias A, Arias M, Santiago P, et al. Benign breast lesions that simulate malignancy: magnetic resonance imaging with radiologic-pathologic correlation. Curr Probl Diagn Radiol. 2007;36(2):66-82.

(25.) diFlorio-Alexander RM, Marotti JD, Bond JS, et al. Breast MRI-detected cystic apocrine metaplasia: imaging features with microvessel analysis and histologic correlation. AIR Am J Roentgenol. 2015;204(1):211-218.

(26.) Khoury T, Kumar PR, Li Z, et al. Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions. Mod Pathol. 2016;29(1):25-33.

(27.) Susnik B, Day D, Abeln E, et al. Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. Clin Breast Cancer. 2016;16(6):507-513.

(28.) Rauch GM, Dogan BE, Smith TB, Liu P, Yang WT. Outcome analysis of 9gauge MRI-guided vacuum-assisted core needle breast biopsies. AJR Am J Roentgenol. 2012;198(2):292-299.

(29.) Han BK, Schnall MD, Orel SG, Rosen M. Outcome of MRI-guided breast biopsy. AJR Am J Roentgenol. 2008;191(6):1798-1804.

(30.) Riedl CC, Ponhold L, Flory D, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res. 2007;13(20):6144-6152.

(31.) Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012; 307(13):1394-1404.

(32.) Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43(13):1905-1917.

(33.) Phi X-A, Saadatmand S, De Bock GH, et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer. 2016;114(6):631-637.

(34.) Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148(9):671-679.

(35.) American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). 5th ed. Reston, VA: American College of Radiology; 2013.

Seema B. Jabbar, MD; Beverly Lynch, MD; Stephen Seiler, MD; Helena Hwang, MD; Sunati Sahoo, MD

Accepted for publication February 2, 2017.

Published as an Early Online Release August 7, 2017.

From the Departments of Pathology and Laboratory Medicine (Drs Jabbar, Lynch, Hwang, and Sahoo), and Radiology (Dr Seiler), University of Texas Southwestern Medical Center, Dallas. Dr Jabbar and Dr Lynch contributed equally to the study.

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Sunati Sahoo, MD, Department of Pathology and Laboratory Medicine, Clements University Hospital, University of Texas Southwestern Medical Center, Dallas, TX 75390-9234 (email: sunati.sahoo@utsouthwestern.edu).

Please Note: Illustration(s) are not available due to copyright restrictions

Caption: Figure 3. A 43-year-old woman underwent magnetic resonance imaging (MR!) for assessment of extent of disease. A, Sagittal postcontrast T1 MRI scan depicts a 5-cm nonmass enhancing lesion. B, The lesion shows persistent kinetics. C, The biopsy shows radial scar with columnar cell change and papillomatosis (hematoxylin-eosin, original magnification X4).

Caption: Figure 4. A 49-year-old woman presented for high-risk screening magnetic resonance imaging (MRI). A, Axial maximum intensity projection subtraction image shows a 7-mm enhancing mass lesion in the right breast (arrow). B, The lesion shows delayed plateau kinetics. C, An MRI-guided biopsy shows an intraductal papilloma (hematoxylin-eosin, original magnification X2).

Caption: Figure 5. A 33-year-old woman presented for high-risk screening magnetic resonance imaging (MRI). A, An axial postcontrast subtraction image shows a 5-cm regional clumped area of enhancement in the right breast. B, This area exhibits washout kinetics. C, An MRI-guided biopsy of nonmass enhancement shows columnar cell lesion (hematoxylin-eosin, original magnification X10).

Caption: Figure 7. A 43-year-old woman underwent magnetic resonance imaging (MRI) for extent of disease evaluation. A, Axial postcontrast subtraction image shows a 1-cm enhancing mass in the right breast (arrow). B, The mass shows washout kinetics. C, An MRI-guided biopsy shows tubular carcinoma (hematoxylin-eosin, original magnification X4).

Caption: Figure 8. An 83-year-old woman underwent magnetic resonance imaging (MRI) scan for extent of disease. A, An axial postcontrast subtraction image shows 11-mm clumped nonmass enhancement in right breast (arrow). B, The lesion shows persistent kinetics. C, An MRI-guided biopsy shows invasive lobular carcinoma (hematoxylin-eosin, original magnification X4).

Caption: Figure 10. Kinetic curve assessment of magnetic resonance imaging lesions. The initial upslope/early phase indicates signal intensity during the first 2 minutes after contrast administration, which can be rapid, medium, or slow. The delayed phase begins after the first 2 minutes or when the slope of the curve changes. Persistent kinetics indicates that the signal intensity continues to rise; in plateau kinetics the signal intensity stays constant, and in washout kinetics it drops off. A lesion may show any combination of the initial and delayed phases.
Table 1. Patient Demographics and Magnetic
Resonance Imaging (MRI) Characteristics

Characteristic                         Value

No. of patients                         152
No. of biopsies                         177

Age, y
Range                                  27-83
Mean                                     52

Indication for MRI evaluation, No.
(%) (N= 152)
Extent of disease                     66 (43)
High-risk screening                   59 (39)
Follow-up of indeterminate lesion     27 (18)

BI-RADS scores, No. (%) (N = 177)
0                                      4 (2)
3                                      13 (8)
4                                     145 (82)
5                                      4 (2)
6                                      11 (6)

MRI lesion type, No. (%) (N = 177)
Mass                                  95 (54)
Nonmass                               76 (44)
Focus                                  6 (3)

MRI kinetics, No. (%) (N = 177)
Persistent                            74 (42)
Plateau                               44 (25)
Washout                               30 (17)
Not available                         29 (16)

Abbreviation: BI-RADS, Breast Imaging
Reporting and Data System.

Table 2. Pathologic Findings Based on the Magnetic
Resonance Imaging Indication

            Extent,   HRS,   F/U-IL,    Total,
              No.     No.      No.     No. (%)

Malignant     19       7        5      31 (18)
Atypical       8       11       1      20 (11)
Benign        50       47      29      126 (71)
Total         77       65      35        177

Abbreviations: F/U-IL, follow-up of indeterminate
lesion;HRS, high-risk screening.

Table 3. Pathologic Diagnosis Category

Category                                 No.

Malignant (18%; 31/177)
Invasive ductal carcinoma                13
Invasive lobular carcinoma                4
Ductal carcinoma in situ                 12
Invasive mixed carcinoma                  1
Tubular carcinoma                         1

Atypical epithelial hyperplasia
(11%; 20/177)
Atypical ductal hyperplasia               3
Lobular neoplasia                    17 (12 ALH,
                                       5 LCIS)

Benign (71%;126/177)
Benign breast diagnoses (105/126)
Fibrocystic changes with/without         31
epithelial hyperplasia
Columnar cell lesions                    30
Fibroadenoma and                         14
fibroadenomatoid change
Ductal ectasia                            7
Radial sclerosing lesion                  6
Papilloma                                 7
PASH                                      5
Intramammary lymph node                   3
Fat necrosis                              1
Hemangioma                                1
Normal breast tissue (21/126)

Abbreviations: ALH, atypical lobular hyperplasia;
LCIS, lobular carcinoma in situ;PASH, pseudoangiomatous
stromal hyperplasia.

Figure 1. Magnetic resonance imaging lesion
type and corresponding pathology diagnosis.

                   Benign      Atypical      Malignant
                   (n=126)    Epithelial       (n=31)
                              Hyperplasia
                                 (n=20)

Mass (n=95)          65%           14%           21%
                   (62/95)       (13/95)       (20/95)

Non-mass (n=76)      76%           10%           14%
                   (58/76)       (7/76)        (11/76)

Focus (n=6)          100%
                    (6/6)

Note: Table made from bar graph.

Figure 2. Magnetic resonance imaging kinetics
and corresponding pathology diagnosis.

                  Benign      Atypical      Malignant
                  (n=126)    Epithelial       (n=31)
                             Hyperplasia
                               (n=20)

Persistent          84%           9%            7%
(n=74)            (62/74)       (7/74)        (5/74)

Plateau             70%           9%            20%
(n=44)            (31/44)       (4/44)        (9/44)

Washout             57%           13%           30%
(n=30)            (17/30)       (4/30)        (9/30)

Not Available       55%           17%           28%
(n=29)            (16/29)       (5/29)        (8/29)

Note: Table made from bar graph.

Figure 6. Magnetic resonance imaging kinetics
of malignant lesions (n = 31).

            Not available    Washout    Plateau    Persistent
                (n=8)         (n=9)      (n=9)       (n=5)

Mass             25%           40%         25%         10%
(n=20)         (5/20)        (8/20)      (5/20)      (2/20)

Non-mass         27%           9%          36%         27%
(n=11)         (3/11)        (1/11)      (4/11)      (3/11)

Note: Table made from bar graph.

Figure 9. Magnetic resonance imaging kinetics
of benign lesions (n = 126).

            Not Available    Washout    Plateau    Persistent
               (n=16)        (n=17)      (n=31)      (n=62)

Mass             13%            21%        27%         39%
(n=62)         (8/62)        (13/62)     (17/62)     (24/62)

Non-mass         14%            5%         21%         60%
(n=58)         (8/58)         (3/58)     (12/58)     (35/58)

Focus                           17%        33%         50%
(n=6)                          (1/6)      (2/6)       (3/6)

Note: Table made from bar graph.
COPYRIGHT 2017 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Articles
Author:Jabbar, Seema B.; Lynch, Beverly; Seiler, Stephen; Hwang, Helena; Sahoo, Sunati
Publication:Archives of Pathology & Laboratory Medicine
Article Type:Report
Geographic Code:1USA
Date:Nov 1, 2017
Words:5215
Previous Article:The Accuracy of the Sysmex UF-1000i in Urine Bacterial Detection Compared With the Standard Urine Analysis and Culture.
Next Article:A Complete Histologic Approach to Gastrointestinal Biopsy From Hematopoietic Stem Cell Transplant Patients With Evidence of Transplant-Associated...
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |